Gilead’s drug pricing in the crosshairs again in wake of OK to use remdesivir against Covid-19

Gilead Sciences Inc. plans to spend $1 billion on its Covid-19 drug remdesivir. Now some members of Congress and health care watchdogs want to know how much consumers will pay. In a letter Thursday to Health and Human Services director Alex Azar, Democratic Reps. Lloyd Doggett of Texas and Rose DeLauro of Connecticut asked for an "appropriate accounting" of taxpayer-backed research into the once-failed Ebola virus treatment that on Friday won Food and Drug Administration emergency use authorization?

Click to view original post